CD274 and leukemia: To determine whether IL-6 loss could also enhance the efficacy of PD-L1 blockade and promote anti-leukemia immune responses, we treated WT and IL-6 KO leukemic mice with PD-L1 inhibitors and monitored disease progression and survival.